title: [Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma].
abstract: Clinical and experimental effects of neoadjuvant treatment of endometrial cancer patients with non-steroidal aromatase inhibitors: letrozole (femara, n=10, 2.5 mg/day, 14 days), anastrozole (arimidex, n=15,1 mg/day, 28 days) and exemestane (aromazine, n=13, 25 mg/day, 14 days) were compared. Administration of anastrozole was mostly frequently followed by pain relief in the lower abdomen and/or decreased rates of uterine discharge. Endometrial wall thickness (M-echo signal) decreased significantly in 60% of patients receiving anastrozole, exemestane - 58.3% and letrozole - 40%. Substantial drop in intratumoral aromatase and blood estradiol levels occurred more frequently after anastrozole and letrozole while progesterone receptor levels in tumor were markedly lower after exemestane administration. Assay of blood LH (except letrozole), FSH and cholesterol appeared to be of less relevance. On the contrary, significance of assessment of marker Ki-67 expression, which, in the case of anastrozole, dropped in 6 out of 12 patients after a 28-day course, could hardly be underestimated.
authors: L M
authors: LM
authors: Bershteĭn
authors: M A
authors: MA
authors: Danilova
authors: A Iu
authors: AIu
authors: Kovalevskiĭ
authors: E D
authors: ED
authors: Gershfel'd
authors: T E
authors: TE
authors: Poroshina
authors: T E
authors: TE
authors: Tsyrlina
authors: I E
authors: IE
authors: Meshkova
authors: E A
authors: EA
authors: Turkevich
authors: S Ia
authors: SIa
authors: Maksimov
mesh_terms: D000328:Adult; D000368:Aged; D000077384:Anastrozole; D000730:Androstadienes / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001141:Aromatase / Q000378:metabolism; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism*; D017024:Chemotherapy, Adjuvant; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000097:blood; D000077289:Letrozole; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D009570:Nitriles / Q000627:therapeutic use; D011980:Receptors, Progesterone / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D000730:Androstadienes; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D009570:Nitriles; D011980:Receptors, Progesterone; D014230:Triazoles; D000077384:Anastrozole; D004958:Estradiol; D000077289:Letrozole; D001141:Aromatase; C056516:exemestane